About ProMetic

 

ProMetic is a global biopharmaceutical company offering technologies for large-scale drug purification, drug development, proteomics (the study of proteins), and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission of bringing to market effective, innovative, lower cost products for the treatment of hematological and nephrological disorders and cancer. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the USA and Canada, manufacturing facilities in the UK and business development activities in the USA, Europe, Asia and in the Middle-East. ProMetic focuses its activities in the Protein Technologies and Therapeutics markets.

Therapeutics

Orally active PBI-1402 Hematology – New Chemical Entities (NCEs) Oncology – New Chemical Entities (NCEs)

Advancing in clinical trials for the treatment of anemia:

  • Chemotherapy-induced anemia
  • Cancer related anemia
  • Anemia associated with Chronic Kidney Disease
  • Proprietary additions to PBI-1402
  • Confirmed erythropoietic activity in vivo
    PBI-4050
    PBI-4265
    PBI-4283
    PBI-4299
  • Promising new lead compounds for the treatment of neutropenia
  • Confirmed anti-cancer activity in vivo
  • Most compounds orally active
  • Could allow for lower doses of chemotherapy, resulting in less side effects like anemia / neutropenia
    PBI-0110
    PBI-1393
    PBI-1522
    PBI-1668
    PBI-1737

Protein Technologies

Prion Capture Technology Bioseparation Products Human Plasma-derived Therapeutics
  • P-Capt® filters to remove infectious prions from blood and blood components
  • Prion capture affinity resin scaled-up for industrial process to remove prions from plasma-derived products
  • To enhance detection of “mad cow disease” in cattle and vCJD in humans
  • Mimetic Ligand™ for large-scale manufacturing
  • Mabsorbents® ligands targeting the purification of MAbs and Fabs
  • Fabsorbent™ for antibody fragment purification
  • Other Affinity Adsorbents
  • Hyperimmune Hepatitis B
  • Hyperimmune CMV
  • Plasminogen, Factor VIII
  • Rare bleeding disorders
  • Fibrinogen
  • VIG, Alpha-1 antitrypsin
  • Other proteins targeted for rare disorders (Orphan Drugs)